We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Self-Assembled Polymer Complexes Have Potential Drug Delivery Role

By LabMedica International staff writers
Posted on 28 Jan 2015
Drug developers have demonstrated the possibility of using mixtures of inert polymers with different configurations and tacticities that self-assemble without outside stimulus (stereocomplexation) to construct active particles that have potential use for controlled release and delivery applications.

Investigators at the University of Warwick (United Kingdom) prepared stereocomplex micelles from a mixture of poly(L-lactide)-b-poly(acrylic acid) and poly(D-lactide)-b-poly(acrylic acid) diblock copolymers in water via crystallization-driven self-assembly. More...
They reported in the December 17, 2014, online edition of the journal Nature Communications that during the formation of these stereocomplex micelles, an unexpected morphological transition resulted in the formation of dense crystalline spherical micelles rather than cylinders.

The investigators theorized that each of the component polymers could carry an inactive drug precursor. When placed in close proximity, the component polymers would undergo stereocomplexation to form a new molecule containing the now active drug. The new particles would be taken up by cells where they would break down and release their drug cargo.

"We conceive that in the blood stream the particles would not be able to interact sufficiently to lead to release, only when they are taken into cells would the release be able to happen", said senior author Dr. Andrew Dove, professor of chemistry at the University of Warwick. "In this way, the drug can be targeted to only release where we want it to and therefore be more effective and reduce side effects. This research raises new possibilities in how we can administer medical treatments. We are planning to study this as a new treatment for cancer but the principle could potentially be applied to a wide range of diseases."

Related Links:
University of Warwick



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
HPV Test
Allplex HPV28 Detection
New
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.